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Abstract
Background: Rapid progression of residual tumor after radiofrequency ablation (RFA) of hepatocellular carcinoma
has been observed increasingly. However, its underlying mechanisms remain to be clarified. The present study was
designed to determine whether low temperature of RFA at the target sites facilitates rapid progression of residual
hepatic VX2 carcinoma and to clarify the possible underlying mechanisms.
Methods: The residual VX2 hepatoma model in rabbits was established by using RFA at 55, 70 and 85°C. Rabbits
that were implanted with VX2 hepatoma but did not receive RFA acted as a control group. The relationship
between rapid progression of residual hepatic VX2 carcinoma and low temperature of RFA at the target sites was
carefully evaluated. A number of potential contributing molecular factors, such as proliferating cell nuclear antigen
(PCNA), matrix metalloproteinase 9 (MMP-9), vascular endothelial growth factor (VEGF), hepatocyte growth factor
(HGF) and Interleukin-6 (IL-6) were measured.
Results: The focal tumor volume and lung metastases of RFA-treated rabbits increased significantly compared with
the control group (P < 0.05), and the greatest changes were seen in the 55°C group (P < 0.05). Expression of
PCNA, MMP-9, VEGF, HGF and IL-6 in tumor tissues increased significantly in the RFA-treated groups compared
with the control group, and of the increases were greatest in the 55°C group (P < 0.05). These results were
consistent with gross pathological observation. Tumor re-inoculation experiments confirmed that low temperature
of RFA at the target sites facilitated rapid progression of residual hepatic VX2 carcinoma.
Conclusions: Insufficient RFA that is caused by low temperature at the target sites could be an important cause of
rapid progression of residual hepatic VX2 carcinoma. Residual hepatic VX2 carcinoma could facilitate its rapid
progression through inducing overexpression of several molecular factors, such as PCNA, MMP-9, VEGF, HGF and IL-6.
Background
Hepatocellular carcinoma (HCC) is still one of the most
important diseases for health care systems due to its
high morbidity, mortality and increasing incidence
worldwide [1]. Although hepatic resection and trans-
plantation have been considered as the main curative
therapies for HCC, the vast majority of patients are not
eligible when this tumor is detected. Only about 20% of
HCC cases are resectable [2,3]. Currently, various local
ablative therapies, such as radiofrequency ablation
(RFA), have been accepted as an alternative treatment
option for HCC, because of its several advantages, such
as definitive therapeutic effect, minimal invasiveness,
repeatability, safety, and shorter hospitalization [3].
At present, residual tumor is one of the main obsta-
cles that greatly hinders the effectiveness of RFA for
HCC [4]. The residual tumor cannot be entirely avoided
for several reasons, such as the mechanisms of RFA, the
pathological characteristics of HCC, and the anatomical
traits of the liver. The reasons for residual tumor can be
categorized as follows: First, the target temperature for
ablation cannot be easily reached due to the “heat sink”
effect of blood vessels, especially large vessels, within or
around the tumor [5]. Second, the operator might
deliberately reduce the local intensity of RFA to avoid
unintended injury when the tumor is adjacent to an
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Third, the performance of overlapping ablation in a
mathematically irregular fashion is difficult, especially by
the percutaneous route. As a result, nests of viable
tumor cells remain in the clefts between the incomple-
tely fused coagulation zones. Finally, the microvascular
invasion area that surrounds the main tumor in HCC is
sometimes wider than expected, or undetected micro-
scopic satellite tumor lesions might be present [6].
Since 2001, rapid progression of residual tumor after
RFA of HCC has been observed increasingly [7,8]. Cumu-
lative evidence has demonstrated that residual tumor
after RFA might exhibit an aggressive phenotype and
unfavorable prognosis [9], and even change to sarcoma
[10], which leads to deterioration of the patient’sc o n d i -
tion. The conventional concepts of residual tumor have
been greatly altered recently. It is believed that clarifying
the underlying mechanisms of rapid progression of resi-
dual tumor might have a significant effect on the thera-
peutic principle and strategy of RFA for HCC [8].
Based on analysis of the aforementioned risk factors,
we hypothesized that low temperature of RFA at the tar-
get sites, which leads to incomplete ablation, might play
an important role in facilitating rapid progression of
residual tumor of HCC after RFA. The present study
was designed to test this hypothesis and to clarify the
possible underlying mechanisms.
Methods
Animals and tumor inoculation
The experiments were performed with New Zealand
white rabbits that weighed 2.5-3.0 kg. The experiments
were approved by the Animal Care Committee of Capital
Medical University, Beijing, China and were performed in
accordance with the institutional guidelines. The animals
were anesthetized with an intravenous injection of
35 mg/kg pentobarbital. The animals were allowed food
and water ad libitum between the various procedures. A
schematic diagram has been produced and added to illus-
trate the experimental procedures (Fig. 1). VX2 carci-
noma was used to establish the model of HCC. VX2
carcinoma is an anaplastic squamous cell carcinoma that
is derived from a virus-induced papilloma in wild rabbits,
but appears as a carcinoma in the domestic species. VX2
tumors were first grown for 2 weeks on the hind legs of
carrier rabbits and then were harvested after they reached
a size of 1.5 cm. The harvested tumors were placed into
saline solution and cut into cubes of 1 mm
3.O n l yp o r -
tions of tumor tissue that did not show any macroscopic
signs of necrosis were used. Abdomens of the recipient
rabbits were shaved and prepared with povidone iodine,
and a midline subxyphoid incision was made. The
anterior surface of the liver was exposed and one of the
prepared cubes of tumor tissue was implanted in the left
lobe of the liver using a 21-gauge angioneedle (Becton
Dickinson, Sandy, UT, USA). This method allowed the
growth of a solitary, well-demarcated tumor. There was
only one inoculation site in each liver. Proper aseptic
technique was rigorously observed during each inocula-
tion. After surgery, the animals were returned to their
cages, kept warm, and monitored in the animal labora-
tory until they recovered from anesthesia. An HDI 5000
ultrasound system (Philips Healthcare, Bothell, WA,
USA) with a 7.5-MHz linear probe was used to monitor
the tumor size. Based on the methods described pre-
viously[11,12] and our experimental design, VX2 carci-
noma nodules > 2.0 cm in diameter were considered
appropriate for RFA. The period for tumors to reach the
size of 2.0 cm ranged from 16 to 18 days. All inoculations
were performed by the same individual investigator, who
inoculated specimens of the same tumor into all rabbits
to minimize inter-animal variations in tumor growth rate.
Figure 1 Schematic diagram of the whole experimental plan.
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The RFA procedure for residual hepatic VX2 carcinoma
was standardized in advance as depicted in Fig. 1 and
Fig. 2. Sixty rabbits were randomly divided into four
groups of 15: group I was treated with RFA at 55°C;
group II was treated with RFA at 70°C; group III was
treated with RFA at 85°C; and the control group received
laparotomy, RFA probe puncture but no ablation. RFA
was performed using the same anesthesia protocol as for
carcinoma implantation. Two grounding pads were
applied to the animal’s flank before RFA. Abdomens of
the experimental rabbits were shaved and prepared with
povidone iodine, and a midline subxyphoid incision was
made. The tumor size was measured and the tumor was
ablated. The tumor center was also designated as the
RFA center. The measured minor axis of the tumor was
used to guide the release of the RFA needle electrode.
Thus, residual tumor was left on both sides of the mea-
sured major axis of the tumor (shadowed area depicted
in Fig. 2). An RF current generator (Model 1500X
Generator; RITA Medical Systems, Manchester, GA,
USA) was used to generate RF energy. To deliver RF
energy, we used a 14-gauge expandable RF needle elec-
trode (StarBurst™ XL; RITA Medical Systems), 10 cm in
length. Each ablation cycle lasted for 5 min.
Gross pathological analysis
The rabbits were sacrificed by injecting an overdose of
ketamine and xylazine 10 days after RFA. The liver and
lungs were carefully dissected and excised. The number
and size of masses were noted. The pathological findings
could thus be compared directly with the tumor num-
bers, volumes and locations. Quantitative evaluation of
the lung metastatic nodules was made by two observers
using the following procedures: macroscopic study by
stereoscopic magnifying glass (Olympus SZH, Zeiss
Stemi DV4, Germany) and counting the metastatic
nodules on the pleural surface of the whole lobules [13].
The variation between the observers’ findings was < 5%.
Immunohistochemical analysis
The streptavidin-peroxidase two-step method was used for
immunohistochemical detection of matrix metalloprotei-
nase 9 (MMP-9), vascular endothelial growth factor
(VEGF) and proliferating cell nuclear antigen (PCNA).
Representative 5-μm tissue sections were cut from paraf-
fin-embedded specimens. The sections were washed three
times for 3 min with PBS, and blocked with a solution of
30 mL/L hydrogen peroxide in ethanol for 10 min at room
temperature. They were immersed in 30 mL/L normal
horse serum for 10 min at room temperature. The sec-
tions were incubated for 1 h with primary antibodies
(mouse monoclonal antibodies; Abcam, Cambridge, UK)
specific to MMP-9 (dilution 1:50), VEGF (dilution 1:50) or
PCNA (dilution 1:100). Negative controls consisted of tis-
sue sections incubated with Tris-buffered saline (TBS)
instead of the primary antibody. The immunoreactivity
was then visualized by incubating the samples in 3,3’-dia-
minobenzedine. Finally, the slides were counterstained
with hematoxylin. To evaluate the expression of MMP-9,
VEGF and PCNA, all slides were examined and scored by
two independent pathologists who were blinded to the
animal data. A few cases with discrepant scores were ree-
valuated to reach a final agreement. Any slides that exhib-
ited diffuse immunostaini n go r>5 0 %t u m o rc e l l sw e r e
classified as (++), > 10% but < 50% as (+), and < 10% as (-).
Western blotting
Proteins for Western blotting were isolated from fresh-fro-
zen tissue using T-Per extraction reagent (Pierce
Biotechnology, Rockford, IL, USA) according to the manu-
facturer’s recommendations. The supernatants were frozen
at -80°C until use. The proteins were fractionated by 10%
SDS-PAGE and followed by electrotransfer onto nitrocel-
lulose filters (Bio-Rad, CA, USA). The filters were blocked
at 4°C overnight with a blocking buffer (pH 7.6) that con-
tained 5% non-fat dry milk. The filters were incubated
with a primary monoclonal antibody to MMP-9 (1:200;
Abcam), VEGF (1:200; Abcam), PCNA (1:200; Abcam),
and a secondary antimouse HRP-antibody (1:2000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at
room temperature. Immunoreactive bands were visualized
using ECL detection reagents (Amersham Pharmacia Bio-
tech, Little Chalfont, Bucks, UK).
Figure 2 Sketch of residual hepatic VX2 carcinoma following
RFA. The oval-shaped area of “adbe” represents the whole tumor.
The line “ab” is the minor axis of the tumor and the line “de” is the
major axis. The tumor center was also designated as the RFA center.
The measured minor axis of the tumor was used to guide the
release of the RFA needle electrode. Thus, residual tumor was left
on both sides of the measured major tumor axis (shadowed area).
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Expression of hepatocyte growth factor (HGF) in tissues
was measured using the ELISA Kit for Rabbit HGF
according to the manufacturer’s instructions (USCN Life
Science, Wuhan, China). Expression of interleukin 6
(IL-6) in tissues was measured using the ELISA Kit for
Rabbit IL-6 according to the manufacturer’s instructions
(USCN Life Science, Wuhan, China).
Tumor reinoculation
The rabbits were sacrificed and the liver tumors were har-
vested simultaneously 10 days after RFA. The harvested
tumors were placed in saline solution and cut into cubes
o f1m m
3. Only portions of tumor tissue that did not
show any macroscopic signs of necrosis were used. The
tumor tissue was reinoculated subcutaneously into the
hind legs of the rabbits as depicted in Fig. 1. Tumor sizes
were measured every 1-2 days, with tumor volumes calcu-
lated according to the formula [14]: V = ab
2/2, where, a is
the longest and b the smallest diameter of the tumor
in vivo. Rabbits were sacrificed 21 days after reinoculation
or when they became moribund. The tumor, liver and
lungs were carefully dissected and examined.
Statistical analysis
Data were presented as the means ± SD for the
indicated number of separate experiments. Statistical
analysis was performed using SPSS version 11.5.
One-way ANOVA followed by the Newman-Keuls test,
Kruskal-Wallis H test, Mann-Whitney test and Student’s
t test were used to evaluate statistical significance and
P < 0.05 was considered significant.
Results
Effects of low temperature of RFA at the target sites on
growth of hepatic VX2 carcinoma
We showed in our previous experiments that residual
hepatic VX2 carcinoma could be seen microscopically in
groups I, II and III. We determined the effects of 5 min
RFA at each temperature on the growth of hepatic VX2
carcinoma. The changes in tumor volume were 24.21 ±
3.94 cm
3 in group I, 17.28 ± 1.84 cm
3 in group II and
15.48 ± 0.91 cm
3 in group III, which were all larger
than that in the control group (12.63 ± 1.87 cm
3). It
seemed that the lower the temperature of RFA was, the
larger the tumor volume was (Fig. 3).
Effects of low temperature of RFA at the target sites on
lung metastasis of hepatic VX2 carcinoma
We examined by gross observation lung metastasis of
hepatic VX2 carcinoma after RFA at low temperature.
Quantifiable metastatic nodules were taken to be those
structures of a white-grey coloration that could be
distinguished on the lung surface and which was
sufficiently separated from each other to be counted
individually (Fig. 4A and 4B). The numbers of metastatic
nodules are shown in Fig. 5. The control group had
between 55 and 80 metastatic nodules randomly distrib-
uted over the lung surface, with a mean of 69.0 ± 10.5.
Group I showed a mean of 302.2 ± 21.6, group II, a
mean of 137.2 ± 16.3, and group III, a mean of 99.6 ±
10.5. Group I was treated with the lowest temperature,
therefore, it showed the greatest increase in metastatic
nodules compared with all the other groups (P < 0.05).
Immunohistochemical assay
MMP-9, VEGF and PCNA were found to be mainly
expressed in cancerous lesions, but also in some normal
tissues (Fig. 6). In vitro cell invasiveness was assessed
using anti-MMP-9 antibody. In vitro cell proliferation
and angiogenesis were evaluated using anti-PCNA and
anti-VEGF antibodies, respectively (Fig. 6). The percen-
tage of positive MMP-9, VEGF and PCNA tumor cells
in the RFA treatment groups were markedly higher than
that in the control group (Table 1, P < 0.05). Compared
with groups II and III, the percentage of positive MMP-
9, VEGF and PCNA tumor cells in group I was even
higher (P < 0.05).
MMP-9, VEGF and PCNA expression in residual hepatic
VX2 carcinoma tissues
Expression of MMP-9 in tumor tissues was markedly
decreased in the control group, and incomplete RFA
due to low temperature at the target sites significantly
increased MMP-9 level in the other groups (Fig. 7).
Similarly, incomplete RFA significantly elevated protein
expression of VEGF and PCNA in groups I, II and III.
At the same time, expression of VEGF and PCNA was
markedly decreased in tumor tissues in the control
Figure 3 Growth of hepatic VX2 carcinoma after insufficient
RFA due to low temperature at the target sites. Data were
expressed as means ± SD of three independent experiments. (*P <
0.05, groups I, II and III vs. control group. #P < 0.05, group I vs.
groups II and III, by one-way ANOVA and Newman-Keuls test).
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was, the higher was the expression of MMP-9, VEGF
and PCNA in residual hepatic VX2 carcinoma tissues.
These results had a similar trend as those of the immu-
nohistochemical assays.
Tissue levels of HGF and IL-6 at the time of animal killing
To assess whether any cytokines from the tumor micro-
environment might be involved in rapid tumor progres-
sion after incomplete RFA, the levels of HGF and IL-6
were determined in tumor and normal tissues from the
same liver at the time of animal killing. Expression of
HGF and IL-6 in the tumor tissues of group I increased
dramatically in comparison with that in the control
g r o u p .A tt h es a m et i m e ,t h ec o n c e n t r a t i o n so fH G F
and IL-6 in non-ablated liver tissues in group I were
much higher than those in liver tissues in the control
group (Fig. 8).
Measurement of tumor growth and metastasis after
reinoculation
To demonstrate further the role of low temperature of
RFA at the target sites in the rapid progression of resi-
dual hepatic VX2 carcinoma, tumor tissues that survived
the first RFA at 55°C were reinoculated to other normal
rabbits. The tumor growth and metastasis were carefully
observed individually. It was found that tumor growth
and lung metastasis in the RFA groups were much more
obvious than in the control group (Figs. 9 and 10).
However, no liver metastasis was detected in any of the
groups.
Discussion
It was demonstrated directly or indirectly in our study
that residual tumor was prone to proliferation, invasion
and metastasis when the local ablative temperature was
not sufficiently high. Besides, it seemed that the lower
the target temperature was, the more significant were
the local proliferation and distant metastasis (e.g. to the
lungs) of the tumor. It is known that different cells,
such as tumor cells, have different endurance to heat.
Some cells can even survive high temperature from 50-
55°C. However, cells can seldom survive temperatures
above 55°C [9]. Therefore, it seems that most residual
tumor and rapid progression should occur when the
temperature is below 55°C, which is consistent with the
results of our study.
In clinical settings, although the target temperature
can be set as high as 105-115°C during RFA, only the
tissues that surround the electrodes can reach that tem-
perature [15]. In fact, the real temperature of the tumor
tissue between the two adjacent electrodes is lower than
the target temperature because of the “heat sink” effect
of blood flow [5]. Residual tumor can occur whenever
Figure 5 Frequency of pulmonary metastatic nodules in the
control group and groups treated with RFA at different low
target temperatures. Data were expressed as means ± SD of three
independent experiments. (*P < 0.05, groups I, II and III vs. control
group. #P < 0.05, group I vs. groups II and III by one-way ANOVA
and Newman-Keuls test).
Figure 4 Macroscopic characteristics of pulmonary metastatic nodules. A. Macroscopic view of the lung. B. Fractionated view of the lung,
which has been magnified to show the details of the metastatic nodules.
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present study, the VX2 nodules were transplanted into
the liver rather than derived from the liver itself, there-
fore, the feeding artery and the heat sink effect were less
than those for HCC. The real ablative temperature of
the tumor might be nearer to the target temperature,
compared with the clinical situation. This was why we
chose 85°C as the highest RFA temperature.
At present, a large number of molecular factors have
been shown to be associated with HCC invasion and
metastasis, such as PCNA, MMP-9, VEGF, HGF and IL-
6. PCNA is a nuclear protein that plays a key role in
cell proliferation, DNA repair and cell cycle control
[16]. In cirrhotic patients, a high level of PCNA immu-
nolabeling is associated with an increased risk of HCC
[17,18], and in HCC, high PCNA values are associated
with poor prognosis [17]. Cell invasion is a major com-
ponent of the complex multistep process of tumor
metastasis. Invasion of malignant tumor cells requires
destruction of basement membranes and proteolysis of
extracellular matrix (ECM). Of the several families of
ECM-degrading enzymes, the most extensive are the
MMPs, which are a large family of structurally related
zinc endopeptidases that collectively degrade most of
the ECM components [19,20]. Among previously
reported human MMPs, MMP-9 is thought to be a vital
enzyme for degrading type IV collagen and is postulated
to play an important role in HCC invasion and metasta-
sis [21,22].
Tumor angiogenesis is another crucial step in the
growth and metastasis of cancer, including HCC, and
has drawn much attention in recent years [23,24].
Hence, the molecular basis of tumor angiogenesis has
been a major interest in the field of cancer research.
The VEGF pathway is well established as an important
driving force of this process [25]. To date, increasing
evidence indicates that tumor-stromal cell interactions
have a crucial role in tumor initiation and progression
[26]. These interactions modify cellular compartments,
which leads to the co-evolution of tumor cells and their
Figure 6 Immunohistochemical staining for MMP-9, VEGF and PCNA in residual hepatic VX2 carcinoma tissues. Original magnifications:
MMP-9 and VEGF, ×400; PCNA, ×200. A, control group; B, group I; C, group II; D, group III.
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and PCNA
Group N Expression
density
No of cases % P
MMP-9 I 15
++ 13 86.67 < 0.01
+ 2 13.33
- 0 0.00
II 15
++ 5 33.33
+ 9 60.00
- 1 6.67
III 15
++ 4 26.67
+ 10 66.67
- 1 6.67
Control 15
++ 0 0.00
+ 7 46.67
- 8 53.33
VEGF I 15
++ 12 80.00 < 0.01
+ 3 20.00
- 0 0.00
II 15
++ 5 33.33
+ 9 60.00
- 1 6.67
III 15
++ 3 20.00
+ 10 66.67
- 2 13.33
Control 15
++ 0 0.00
+ 6 40.00
- 9 60.00
PCNA I 15
++ 11 73.33 < 0.01
+ 4 26.67
- 0 0.00
II 15
++ 4 26.67
+ 10 66.67
- 1 6.67
III 15
++ 2 13.33
+ 12 80.00
- 1 6.67
Control 15
++ 0 0.00
+ 5 33.33
- 10 66.67
MMP-9: matrix metalloproteinase 9; VEGF: vascular endothelial growth factor;
PCNA: proliferating cell nuclear antigen. Any slides that exhibited diffuse
Figure 7 M M P - 9 ,V E G Fa n dP C N Ae x p r e s s i o ni nr e s i d u a l
hepatic VX2 carcinoma tissues. A, MMP-9; B, VEGF; C, PCNA. 1,
control group; 2, group III; 3, group II; 4, group I.
Figure 8 RFA might affect the expression of HGF and IL-6 in
liver and tumor tissues. A, Concentration of HGF; B, Concentration
of IL-6. Liver tissues represented the normal tissues from the same
liver which was treated with RFA. Data were expressed as means ±
SD of three independent experiments. (*P < 0.05, groups I, II and III
vs. control group. #P < 0.05, group I vs. groups II and III, by one-way
ANOVA and Newman-Keuls test).
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produced by non-parenchymal liver cells, and is a multi-
functional cytokine of the tumor microenvironment of
HCC [27]. HGF accomplishes most of the functions of
the invasive program in carcinomas (loss of adhesive
junctions, motility, angiogenesis, and survival/apoptosis).
HGF receptor, also known as c-Met, plays important
roles in angiogenesis and tumor growth [28]. It has been
reported that c-Met expression is significantly higher in
the invasive type of HCC, as determined by gross type,
vessel invasion, intrahepatic metastasis and histological
type, and induction of c-Met might be used as a indi-
cator of HCC progression, especially intrahepatic
metastasis [29].
IL-6 is a multifunctional regulator of the immune
response and hematopoiesis. Recently, it has been
reported that expression of IL-6 is correlated with prog-
nosis in various cancer patients [30-32]. Kanazawa et al.
[32] have reported that IL-6 can directly influence cell
proliferation and the invasion potential as the first step
of tumor metastasis. Hong et al. [33] believe that thera-
peutic targeting of IL-6 and its receptor in cancer has a
strong biological rationale, and there is preliminary evi-
dence to suggest that targeting of the IL-6 system might
be beneficial in the treatment of cancer. In the present
study, it was shown that expression of PCNA, MMP-9,
V E G F ,H G Fa n dI L - 6i nt u m o rt i s s u e si ng r o u p sI ,I I
and III, which received incomplete RFA, increased
remarkably. Furthermore, it seemed that the lower the
target temperature of RFA was, the higher was the
expression of these molecular factors. This was consis-
tent with the results of tumor inoculation and reinocula-
tion studies. These data suggest that the residual tumor
cells facilitate tumor growth and metastasis through
induction of overexpression of PCNA, MMP-9, VEGF,
HGF and IL-6.
It is important to clarify the underlying mechanisms of
rapid progression of residual HCC after RFA, to opti-
mize the therapeutic principles and strategies of RFA. It
has been reported that HGF/c-Met signaling can acti-
vate multiple signal transduction pathways, including
the Src/focal adhesion kinase pathway, the p120/signal
transducer and activator of transcription 3 pathway, the
phosphoinositide-3 kinase (PI3K)/Akt pathway, and the
MEK/ERK pathway [34,35]. It has been confirmed that
the PI3K/Akt and MEK/ERK pathways play a vital role
in tumor invasion and metastasis [36-40]. Increasing evi-
dence has demonstrated that the HGF/c-Met signaling
pathway could be another valuable pathway for research
on tumor target therapy, besides the VEGF signal path-
way. HGF/c-Met signaling is activated in angiogenesis
and tumor growth, therefore, several strategies have
been explored for inhibiting this pathway. Some inhibi-
tors of the HGF/c-Met signaling pathway have been
Figure 9 Volumes of hepatic VX2 carcinoma 21 days after
reinoculation. A, Photographs of the hepatic VX2 carcinoma of five
rabbits selected from the control group and five from group I. 1,
Group I, RFA at 55°C; 2, control group. The top row shows hepatic
VX2 carcinoma of rabbits treated with RFA, and large tumors were
seen. The bottom row shows hepatic VX2 carcinoma of control
rabbits with smaller tumors. B, 1, group I, RFA at 55°C; 2, control
Figure 10 Lung metastasis of hepatic VX2 carcinoma 21 days
after reinoculation. A, Photographs of the lungs of five rabbits
selected from the control group and five from group I. 1, group I,
RFA at 55°C; 2, control group. The top row shows lungs of rabbits
treated with RFA, and numerous, large, white-grey tumors were
seen. The bottom row shows lungs of control rabbits with fewer
and smaller tumors. B, 1, group I, RFA at 55°C; 2, control group. Data
are expressed as means ± SD of three independent experiments.
(*P < 0.05, by Student’s t test)
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and II clinical trials [41]. In our study, we found that
expression of HGF in tumor tissues after incomplete
RFA was much higher than that in tumor tissues without
RFA. This indicates that the HGF/c-Met signaling path-
way might be involved in the rapid progression of resi-
dual tumor after RFA. Further research in this area could
have potential for enhancing the therapeutic effect of
RFA on HCC. Another significant finding was that
expression of HGF and IL-6 in non-ablated liver tissues
in group I were much higher than those in liver tissues in
the control group. We supposed that both the liver injury
t r i g g e r e db yR F Aa n da u t o c r i ne loop in tumor cells may
involve in it. However, this needs to be confirmed.
Conclusions
In conclusion, the results of this study highlight two
issues. Firstly, insufficient RFA, which is caused by low
temperature at the target sites, could be an important
reason for rapid progression of residual hepatic VX2
carcinoma. Secondly, residual hepatic VX2 carcinoma
might facilitate rapid tumor progression through induc-
tion of overexpression of multiple molecular factors,
such as PCNA, MMP-9, VEGF, HGF and IL-6.
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